Biolab helps Jordanians combat breast cancer by adopting BRCA1 and BRCA2 genetic mutation testing

Biolab, the exclusive Biomnis dealer in the Kingdom, recently announced its collaboration with the Leeds Teaching Hospitals (LTH) in the United Kingdom on the testing for BRCA1 and BRCA2 genetic mutations using modern sequencing technologies.

BRCA1 and BRCA2 are hereditary genetic mutations associated with higher risk of breast cancer. This collaboration with LTH stems from Biolab's continued efforts to raise awareness on the disease and empower Jordanian women to effectively prevent or diagnose the disease during its early stages. The BRCA1 and BRCA2 test helps physicians identify a genetic predisposition to the disease, allowing for the establishment of effective preventative and control mechanisms.

The management of Biolab explained that the BRCA1 and BRCA2 gene mutations testing, which releases results within as little as six to eight weeks, is regarded as a breakthrough in the field of diagnostic medicine as the results offer patients comprehensive data on their predisposition to cancer, allowing them to take the necessary precautions. The management further noted that the adoption of this test in Jordan comes as part of Biolab's long-term strategy to elevate the standards of healthcare within the local community.

Biolab is a pioneer in applying advances in medicine and science to laboratory testing, providing a broad range of medical diagnostic services that spans 700 tests, in addition to offering a wide array of medical, scientific and consultancy services in the fields of health and diagnostics. Leveraging on cutting-edge technology, high caliber staff and an extensive insurance and bank affiliate network, Biolab offers its patients an unparalleled premium experience, prioritizing reliability, accountability and convenience.